Sydney – October 12, 2026 -- The Safety Review Committee (SRC) for Racura Oncology's HARNESS-1 trial has cleared lead drug RC220 to escalate to 100 mg/m2, after finding no dose-limiting toxicities in either Cohort 1 patient. The Phase 1a/b study combines RC220 with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC).